BusinessProlonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast CancerBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessTucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 CongressBy Nasdaq OMXSep 11, 2017, 10:00 AM UTC
